{"id":"W4379521519","doi":"10.1136/annrheumdis-2023-eular.1722","title":"POS0232 POST-MARKETING SAFETY SURVEILLANCE OF TOFACITINIB OVER 9 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"UCB Pharma; Medac; Eisai; Celgene; Biogen; Ortho Dermatologics; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatoid arthritis; Adverse effect; Internal medicine; Safety profile; Ulcerative colitis; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002314193,0.0003151492,0.0005399318,0.0007510644,0.0004031899,0.0008448908,0.0002598528,0.0008580365,0.002452411],"category_scores_gemma":[0.00393369,0.0001515367,0.000725484,0.0006813282,0.0002351703,0.000679443,0.0003126036,0.0008125997,0.0009886905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005706011,"about_ca_system_score_gemma":0.0004823198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008306341,"about_ca_topic_score_gemma":0.0009285812,"domain_scores_codex":[0.9984962,0.0003212098,0.0002034947,0.0002896897,0.0005511729,0.0001381285],"domain_scores_gemma":[0.9964006,0.000684717,0.001529572,0.0001599293,0.0008525925,0.0003725757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007407751,0.0003492592,0.9193275,0.0001616309,0.0002122011,0.0008235396,0.0001770416,0.0002916483,0.00578239,0.0001673023,0.002390714,0.06290896],"study_design_scores_gemma":[0.0002283842,0.005351398,0.9803799,0.00005973335,0.0002459493,0.003426736,0.0002182718,0.0008405652,0.002268301,0.0001921437,0.006765485,0.00002308454],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875746,0.002585596,0.0004100272,0.0005051226,0.00008669207,0.000051675,0.002105817,0.00004361667,0.006636955],"genre_scores_gemma":[0.9958988,0.0003340801,0.0002499328,0.0003979972,0.00009856514,0.0000315865,0.001966382,0.000007650948,0.001015017],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002452411,"threshold_uncertainty_score":0.0122388,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0114334463673926,"score_gpt":0.2519962390943637,"score_spread":0.2405627927269711,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}